Questions? Feedback? powered by Olark live chat software
All Site

Luciferase Reporter Cancer Cell Lines

CAR-T cell-based therapeutics have emerged as a promising immunotherapy forreating specific leukemias, lymphomas, and myelomas. In this exciting approach to treating refractory cancers, T cells are isolated from a patient’s blood via apheresis.

CAR-T cells have proven to be a new type of "living" therapeutic that harnesses the patient’s immune system to recognize specific tumor-associated antigens and redirects the engineered T cells to more specifically target tumor cells.

Click here for more: https://lnkd.in/erGbJbMf
21.03.2023